Constipation
Recent clinical, regulatory, research and industry developments relating to this disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 5 clinical trials expected to report results, the earliest in Q1 2027.
- 3 industry developments reported.
- Q1 2027A 26-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Chronic Idiopathic Constipation (CIC) in Adults
- Q1 2027Effects of Home-based TEA for Abdominal Pain in Patients With Irritable Bowel Syndrome (IBS)
- Q1 2027OMAMA-study - Prevention of Opioid-induced Constipation in Patients With Advanced Cancer
- Q3 2027Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen
- Q4 2027Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation: A Multicenter, Randomized Controlled Trial
Clinical MilestonesViewHide
- 2026-05-14A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (FC) With a 24-week Open-label Treatment ExtensionResults posted
- 2026-01-06A Phase 3, Open-label, Long-term Safety Study of Oral Linaclotide Administered to Pediatric Participants With Functional Constipation (FC) or Irritable Bowel Syndrome With Constipation (IBS-C)Results posted
- 2026-10-05OMAMA-study - Prevention of Opioid-induced Constipation in Patients With Advanced CancerResults expected Q1 2027
- 2026-09-17Effects of Home-based TEA for Abdominal Pain in Patients With Irritable Bowel Syndrome (IBS)Results expected Q1 2027
- 2026-08-18Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush RegimenResults expected Q3 2027
- 2026-08-05Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation: A Multicenter, Randomized Controlled TrialResults expected Q4 2027
- 2026-06-04A 26-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Chronic Idiopathic Constipation (CIC) in AdultsResults expected Q1 2027
Industry & MarketViewHide
- 2026-10-22'Constipation Cookies'; Antibiotics and IBS; Primary Biliary Cholangitis GuidelinesIndustry · MedPage Today — Gastroenterology
- 2026-07-16Common constipation drug may help clear depression brain fogIndustry · Science Daily
- 2026-10-19'Constipation' Lands Patient in Surgery for Unusual AnatomyIndustry · MedPage Today — Gastroenterology
- 2026-10-22Industry'Constipation Cookies'; Antibiotics and IBS; Primary Biliary Cholangitis GuidelinesIndustry · MedPage Today — Gastroenterology
- 2026-10-19Industry'Constipation' Lands Patient in Surgery for Unusual AnatomyIndustry · MedPage Today — Gastroenterology
- 2026-10-05ClinicalOMAMA-study - Prevention of Opioid-induced Constipation in Patients With Advanced CancerResults expected Q1 2027
- 2026-09-17ClinicalEffects of Home-based TEA for Abdominal Pain in Patients With Irritable Bowel Syndrome (IBS)Results expected Q1 2027
- 2026-08-18ClinicalEvaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush RegimenResults expected Q3 2027
- 2026-08-05ClinicalEfficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation: A Multicenter, Randomized Controlled TrialResults expected Q4 2027
- 2026-07-16IndustryCommon constipation drug may help clear depression brain fogIndustry · Science Daily
- 2026-06-04ClinicalA 26-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Chronic Idiopathic Constipation (CIC) in AdultsResults expected Q1 2027
- 2026-05-14ClinicalA Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (FC) With a 24-week Open-label Treatment ExtensionResults posted
- 2026-03-13ClinicalPre- and Post-operative Compared to Post-operative Only Polyethylene Glycol 3350 for Minimally Invasive Urogynecologic SurgeryCompleted
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Original application approval — Treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequa… (2014)
Original application approval — Constella is indicated for the symptomatic treatment of moderate to severe irritable-bowe… (2012)
Original application approval — Resolor is indicated for symptomatic treatment of chronic constipation in adults in whom… (2009)
Original application approval — Treatment of opioid-induced constipation in advanced-illness patients who are receiving p… (2008)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes2
- Gastrointestinal Microbiome2
- Fecal Microbiota Transplantation1
Leading journals1
- Microbiome2
Leading researchers8
- Adams JB1
- Albanese D1
- Borody T1
- Calabrò A1
- Caporaso JG1
- Cavalieri D1
- Chittick L1
- De Felice C1
Affiliations (unnormalised)6
- Biodesign Swette Center for Environmental Biotechnology1
- BioTechnology Institute1
- Center for Immunology1
- Centre for Digestive Diseases1
- Centre for Integrative Biology1
- Department of Experimental and Clinical Biomedical Sciences1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.